David Ruggieri, MD
Cardiovascular Disease · Punta Gorda, FLNPI 1891702965
Payments from drug & device makers
What this record shows
9 manufacturers reported payments, led by Abbott at 54.1% of the total. Reporting peaked in 2019 at $836 and has fallen 92.5% since, to $63 in 2024. That places this record below the midpoint for cardiovascular disease clinicians in FL, where the typical reported total is $2,774.
Across 51 payments — averaging $28.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$782
- Biotronik Inc.$403
- Venclose Inc.$98
- Novo Nordisk$49
- Astellas Pharma US Inc$43
- Cvrx, Inc.$23
- plus $48 from 3 others
What the payments were for
- Speaking & faculty fees$76953%
- Food & beverage$67747%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 2 | $782 |
| Biotronik Inc. | 40 | $403 |
| Venclose Inc. | 1 | $98 |
| Novo Nordisk | 2 | $49 |
| Astellas Pharma US Inc | 2 | $43 |
| Cvrx, Inc. | 1 | $23 |
| Boston Scientific | 1 | $18 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $17 |
| GSK | 1 | $12 |
How this compares
$1,446 in reported general payments places this provider in the 35th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 26 | $33,405 |
| Digoxin | 82 | $1,860 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $1,582 |
| Rosuvastatin Calcium | 63 | $1,320 |
| ClopidogrelClopidogrel Bisulfate | 95 | $1,213 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 41 | $1,070 |
| Atorvastatin Calcium | 92 | $946 |
| Levothyroxine Sodium | 63 | $911 |
| Metoprolol Succinate | 51 | $771 |
| Omega-3 Acid Ethyl Esters | 12 | $637 |
| Pravastatin Sodium | 45 | $515 |
| Potassium Chloride | 15 | $486 |
| Losartan Potassium | 47 | $469 |
| Tamsulosin Hcl | 23 | $450 |
| CefuroximeCefuroxime Axetil | 40 | $400 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Punta Gorda
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
- Neel PatelMaitland$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.